Analisa Kadar Serum Feritin di Karsinoma Payudara  

Oleh:

Atjo, Sriwati ; Bahrun, Uleng ; Hardjoeno

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Indonesian Journal of Clinical Pathology and Medical Laboratory vol. 22 no. 01 (Nov. 2015), page 34-37.
Topik: Serum Ferritin; Karsinoma Payudara; Metastasis

Ketersediaan

Perpustakaan FK Nomor Panggil: I01.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Carcinoma Mammae is a malignant disease originating from mammary parenchyma, and the second largest cause of death in the world. Ferritin is a marker of neoplasia, which levels are increased in non-metastatic carcinoma mammae and more increased in metastatic carcinoma mammae. This cross sectional study was conducted during June 2012 in carcinoma mammae patients of the Wahidin Sudirohusodo Hospital, Ibnu Sina Hospital and Labuang Baji Hospital in Makassar. The aim of this study was to know the serum ferritin levels in metastatic and non-metastatic carcinoma mammae. In this study, 56 samples were obtained and grouped into metastatic and non-metastatic carcinoma mammae patients based on the Tumor, Node, Metastasis (TNM). Ferritin test was conducted by ECLIA method using Elecsys Analyzer Kit 2010 (Roche, USA). The study showed that the average ferritin concentration in advanced stage of carcinoma mammae (155.45 ng/mL) was higher than in the early stage (82.74 ng/m). The Mann Whitney test showed significant differences between the early and advanced stage (p=0.01), the median ferritin value in metastatic carcinoma mammae was higher than non-metastatic (79.85 ng/mL). The Mann Whitney test showed significant differences between metastatic and non - metastatic carcinoma mammae patients (p=0.00). Based on this study, it can be concluded, that ferritin levels can be used as a biomarker to predict the progressivity of carcinoma mammae.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali